FindTrial
Sign In

19CP02

DRUG2 trials

Sponsors

Galapagos, Galapagos Cell Therapeutics

Conditions

Relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)Relapsed/refractory B-Cell non-Hodgkin lymphomaRelapsed/refractory B-cell non-Hodgkin lymphomaRelapsed/refractory multiple myeloma

Phase 1

A phase I/II, multicenter study evaluating the feasibility, safety, and efficacy of point-of-care manufactured GLPG5101 (19CP02) in subjects with relapsed/refractory B-cell non-Hodgkin lymphoma
RecruitingCTIS2022-502661-23-00
GalapagosRelapsed/refractory B-cell non-Hodgkin lymphoma
Start: 2024-06-11Target: 160Updated: 2026-01-23

Phase 3

A long-term follow-up study for patients treated with Galapagos CAR T-cell therapies
RecruitingCTIS2023-510173-34-00
Galapagos Cell TherapeuticsRelapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Relapsed/refractory B-Cell non-Hodgkin lymphoma, Relapsed/refractory multiple myeloma
Start: 2024-07-26Target: 177Updated: 2025-11-28

Related Papers

High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 MCL cohort
Blood2025-11-03
High complete response rates, low dropout rate, and low-grade toxicities in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) receiving GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 DLBCL cohort
Blood2025-11-03
Atalanta-1: A Phase 1/2 Trial of GLPG5101, a Fresh, Stem-like, Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma
Blood2024-11-052 citations
Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5101) in Relapsed/Refractory NHL: Results from the Phase 1 Atalanta-1 Trial
Blood2023-11-025 citations